HRT After Endometrial Cancer: What Actually Changes the Answer

HRT after endometrial cancer is not one answer. The clearest discussable group is carefully selected stage I–II, grade 1–2 endometrioid disease after definitive surgery with no residual or recurrent disease. BGCS/BMS also supports discussion after low- or intermediate-risk disease treated with hysterectomy. Outside that group, guidance becomes more restrictive or openly uncertain. Final pathology decides the zone.

That is the honest headline. The rest of this page explains why two careful clinicians can look at the same history and give you different answers — and which facts make one answer fit you.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Is this page for you?

Answer: This page is for survivors who have finished treatment and need a pathology-based answer about systemic or local hormone therapy. It is not a clearance route for active treatment, possible recurrence, new unexplained bleeding, retained uterus after fertility-sparing care, or anyone trying to bypass gynecologic oncology.

This page is for you if…	This is not the right starting point if…
You finished treatment and want to know whether estrogen is truly ruled out	You are still in treatment, have active or recurrent disease, or are being checked for a possible recurrence
You were told “no” in one sentence and never got a pathology-based reason	You have new vaginal bleeding, new pelvic pain, or another new symptom you have not reported — contact your oncology team promptly
Your main problem is vaginal dryness, painful sex, burning, or urinary symptoms and you want to know whether local treatment is different	You want a prescription without involving the team that knows your cancer history. This page will not help you bypass oncology
You want to know which facts decide the answer and what to bring to the appointment	You want somebody online to guarantee that HRT is safe for you. Nobody honest can do that

What is the 30-second answer on HRT after endometrial cancer?

Answer: Guidance agrees on the clearest group: stage I–II, grade 1–2 endometrioid disease after definitive surgery with no residual or recurrent disease can enter specialist HRT discussion. BGCS/BMS also supports a broader low/intermediate-risk pathway. In higher-risk disease, guidance diverges; those cases are uncertain or contraindicated, not online-clearance cases. Vaginal estrogen is a separate lower-exposure conversation.

Your situation	What current specialist guidance says	Where the decision starts
Selected stage I–II, grade 1–2 endometrioid disease, definitive surgery completed, no residual or recurrent disease	FIGO 2026: systemic HRT may be considered. BGCS/BMS 2024: discuss advantages and disadvantages for low/intermediate risk after hysterectomy	Gynecologic oncologist, with final pathology and treatment record
High-intermediate disease, or high-risk disease with ER- and PR-negative tumors	BGCS/BMS: individualize because risk is unknown. FIGO 2026 is more restrictive for grade 3, non-endometrioid, or stage III–IV disease	Multidisciplinary specialist discussion only
High risk, advanced or metastatic disease that expresses hormone receptors	BGCS/BMS: systemic HRT is not recommended. FIGO 2026 treats stage III–IV, grade 3, and non-endometrioid disease as contraindicated or strongly discouraged for systemic MHT	Oncology-led non-hormonal or palliative symptom plan
Advanced disease in a palliative setting	Quality of life can change the balance; HRT may be discussed case by case (Grade D)	Treating oncology and palliative-care team
Uterine leiomyosarcoma or endometrial stromal sarcoma	Avoid HRT except in narrowly individualized circumstances after alternatives have failed or benefits clearly outweigh risk (BGCS/BMS)	Specialist-only plan
Vaginal dryness, painful sex, burning, or urinary symptoms only	Low-dose vaginal estrogen is treated separately and is considered safe for the majority of women after gynecological cancer, with rare exceptions (Grade B)	Product-specific discussion after healing and oncology review
Still in treatment, possible recurrence, or new unexplained bleeding	This is not an online-HRT decision	Your oncology team now

The newest sources do not draw every boundary the same way. BGCS/BMS 2024 preserves an individualized “unknown” zone for high-intermediate and ER/PR-negative high-risk disease. The July 2026 FIGO position paper is more conservative for stage III–IV, grade 3, and non-endometrioid disease. That disagreement is a reason for oncology review, not a tie to break online.

Stage alone is not enough. Modern risk assessment also uses histology, grade, myometrial invasion, lymphovascular space invasion, molecular class, receptor status, residual disease, and the treatment plan.

Is online HRT care the right starting point?

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

A history of endometrial cancer belongs in specialist-first care. The tool can help separate systemic symptoms from local vaginal symptoms and show the care route that fits your state and insurance. One honest limit: its published safety-gate list does not yet name endometrial cancer as a dedicated question. Use it for routing, but keep this diagnosis specialist-first regardless of the result. It cannot clear HRT after cancer, replace your pathology report, or make an oncology decision.

What did we actually verify for this page?

Answer: We read the current cancer guidance, FDA labels, randomized and observational evidence, the 2026 vaginal-estrogen study, and the provider pages cited below. We did not treat a search snippet, a forum post, or a telehealth marketing claim as medical evidence.

For this audit, The HRT Index checked:

• The British Gynaecological Cancer Society/British Menopause Society 2024 joint guideline, including its graded recommendations for endometrial carcinoma, uterine sarcoma, vaginal estrogen, timing, non-hormonal treatment, and compounded hormones.
• The July 2026 FIGO position paper, including its stage-and-histology eligibility table, local-vaginal-estrogen positions, and its more conservative boundary for systemic MHT in stage III–IV, grade 3, and non-endometrioid endometrial cancer.
• The Society of Gynecologic Oncology 2020 clinical practice statement, endorsed by The North American Menopause Society, including its early-stage, advanced-stage, and uterine-sarcoma recommendations.
• The 2025 ESGO–ESTRO–ESP endometrial-carcinoma guideline, which uses FIGO 2023 staging plus molecular and pathological factors for current risk classification.
• The February 2026 FDA announcement on six relabeled menopause hormone products, the current Divigel label, the prior April 2025 Divigel label, and the current Estring label.
• The Cochrane review of the only randomized trial, the 2021 meta-analysis, and the 2026 matched-cohort study of vaginal estrogen.
• Current FDA labels for Veozah and Lynkuet.
• Current, provider-stated availability, insurance, self-pay, lab, and appointment-change information on Midi's cancer-survivorship page and help center; current medication-status information on Winona's HRT page and the Inner Balance/Oestra product page; and the live Find My HRT Path destination and privacy explanation.

What no source can verify: whether HRT is appropriate for you. That requires the pathology, current disease status, treatment history, symptom target, other contraindications, and a prescriber willing to coordinate with oncology.

Can you take HRT after endometrial cancer?

Answer: Sometimes. The clearest supported group is carefully selected stage I–II, grade 1–2 endometrioid carcinoma after definitive surgery with no residual or recurrent disease. BGCS/BMS also supports discussion for low- or intermediate-risk disease after hysterectomy. Higher-risk guidance is not fully aligned: BGCS/BMS preserves an unknown individualized zone, while FIGO 2026 is more restrictive. Uterine sarcoma has separate rules.

There are three honest zones, and almost every argument online is a fight between people standing in different ones.

Zone 1 — HRT should be discussed

For low- and intermediate-risk endometrial carcinoma after hysterectomy, the BGCS/BMS guideline says clinicians should discuss the advantages and disadvantages of HRT. It also says the limited evidence available has not identified increased recurrence in that selected population. That is a Grade B recommendation, which describes the strength and source of the supporting evidence. It is not a guarantee of safety for an individual.

The July 2026 FIGO position paper reaches the same broad answer for a narrower named group: carefully selected stage I–II, grade 1–2 endometrioid carcinoma after definitive surgery, with no residual or recurrent disease. Its table says systemic MHT may be considered and local vaginal estrogen is acceptable, with OCEBM level 2 evidence.

The older U.S. SGO statement also has the same broad shape: hormone therapy is considered acceptable after early-stage endometrial cancer, with individualized counseling. The U.S. statement is broader and predates FIGO 2023 molecular-risk integration, so it does not replace the more detailed pathology conversation.

Zone 2 — The risk is genuinely unknown

For high-intermediate disease, or high-risk disease with tumors that are both estrogen- and progesterone-receptor negative, the BGCS/BMS guideline says to individualize after discussing theoretical risks and benefits because the HRT risk is unknown. That is Grade D, based largely on expert opinion and extrapolation.

Receptor-negative does not mean “safe.” It means one reason for concern is absent while direct recurrence evidence is still absent too.

Here the current frameworks do not line up cleanly. BGCS/BMS calls high-intermediate and high-risk ER/PR-negative disease unknown and individualized. FIGO 2026 groups stage III–IV, grade 3, and non-endometrioid disease as high risk and says systemic MHT is contraindicated or strongly discouraged. This is not a conflict a reader should settle by choosing the more permissive sentence. It is a specialist discussion about which framework fits the pathology.

Zone 3 — Systemic HRT is not recommended

The same guideline does not recommend systemic HRT for high-risk, advanced, or metastatic endometrial cancer that expresses hormone receptors. FIGO 2026 independently treats stage III–IV, grade 3, and non-endometrioid disease as contraindicated or strongly discouraged for systemic MHT. Uterine leiomyosarcoma and endometrial stromal sarcoma are also treated restrictively because these tumors can be hormone sensitive and endocrine therapies are used in their treatment.

The SGO statement is more categorical for late-stage disease: there are no supporting data for stage III–IV endometrial cancer, so hormone therapy is not recommended. BGCS/BMS adds two pieces of nuance the short U.S. statement does not spell out: high-intermediate disease and ER/PR-negative high-risk disease remain unknown rather than proven safe or unsafe, and palliative quality-of-life goals can justify an individualized discussion.

Notice what all three zones have in common: none can be worked out from the word cancer alone. They require the report.

One line from the BGCS/BMS guideline deserves to survive every blanket refusal: “a gynaecological malignancy is not an automatic contraindication to HRT.” That does not mean HRT is automatically appropriate either. It means the diagnosis should start the reasoning, not end it.

A note on geography and disagreement: BGCS/BMS is British guidance, FIGO 2026 is an international position paper, and SGO is a U.S. statement. They do not draw every high-risk boundary identically. Your clinicians are not required to choose the most permissive wording; they have to decide which framework fits your pathology and treatment context.

Why were you probably told no?

Answer: Unopposed estrogen is an established cause of endometrial cancer in a woman who still has a uterus, and many endometrioid cancers express hormone receptors. That biology creates a rational alarm. The problem begins when a prevention warning about causing a first cancer is treated as a complete recurrence rule after the uterus and tumor have been removed.

The biology is real. The current Divigel label warns that unopposed systemic estrogen increases the risk of endometrial cancer in a woman with a uterus. That is why systemic estrogen normally requires endometrial protection with a progestogen when the uterus remains.

But two questions are being collapsed:

1. Can unopposed estrogen cause a new endometrial cancer in a uterus that is still present? Yes, the risk is established.
2. Does menopausal hormone therapy cause recurrence after a selected endometrial cancer was treated and the uterus removed? The evidence is limited, mostly early-stage, and has not produced a clear harm signal — but it has not proven universal safety.

That distinction is not wordplay. It is the entire reason current specialty guidance does not use one answer for every survivor.

The refusal also runs ahead of the evidence in practice. The SGO statement describes systemic and local hormone therapy as consistently underused among women with a personal history of gynecological cancer. A Swedish survey was blunt enough to put the problem in its title: clinicians were afraid to prescribe despite national guidance. In the 2026 U.S. study of younger endometrial cancer survivors, only 5.6% met the study's vaginal-estrogen-use definition.

This is not a story about women taking too much estrogen. It is a story about women being left untreated.

What survivors actually say

The following fragments come from a Macmillan womb-cancer discussion. They are lived experience, not medical evidence:

“not keen on prescribing HRT”

“help with hot flushes but not the insomnia”

If that sounds like your appointment, you are not imagining the gap. You may have received a medically defensible “no.” You may also have received a reflex “no” from someone who did not have your pathology in front of them. The next step is not to argue for estrogen. It is to ask for the reason in writing.

Which endometrial cancer did you actually have?

Answer: The first split is not “estrogen-driven versus not estrogen-driven.” It is endometrial carcinoma versus uterine sarcoma. Within endometrial carcinoma, current decisions use histology, stage, grade, invasion, LVSI, molecular class, receptor status, residual disease, and treatment. The old Type 1/Type 2 shortcut is no longer enough for this decision.

Many women were told they had “uterine cancer” and never heard the exact diagnosis again. That phrase can cover diseases that do not share the same HRT evidence.

Endometrial carcinoma

This is the population behind the randomized trial and most observational evidence on this page. Endometrioid carcinoma is common, but even within endometrioid disease, stage, grade, LVSI, molecular subtype, receptor status, and residual disease can move a woman into a different risk group.

Serous carcinoma, clear-cell carcinoma, carcinosarcoma, undifferentiated carcinoma, and mixed aggressive histologies carry different recurrence patterns. They cannot be reduced to “not estrogen-driven, so estrogen should be fine.” Aggressive biology and lack of direct HRT data can make clinicians more cautious even when hormone-receptor expression is absent.

Uterine sarcoma

Uterine sarcoma is not endometrial carcinoma. If the diagnosis was leiomyosarcoma or endometrial stromal sarcoma, the endometrial-carcinoma recurrence evidence does not transfer.

The BGCS/BMS guidance says HRT should be avoided after uterine leiomyosarcoma and avoided after endometrial stromal sarcoma unless the individual benefit outweighs the risk. For severe symptoms after leiomyosarcoma, consideration comes only after alternatives have been ineffective and with specialist involvement.

This is not a footnote. It is one of the fastest ways a page about “uterine cancer” can give the wrong woman the wrong reassurance.

Your first question: “What was the exact diagnosis and histology on my final pathology — endometrial carcinoma, carcinosarcoma, leiomyosarcoma, endometrial stromal sarcoma, or something else?”

Which 8 pathology facts change the HRT answer?

Answer: Current endometrial-cancer risk is not a stage lookup. The practical record is eight fields: exact diagnosis, staging system and stage, grade, depth of myometrial invasion, LVSI, molecular class, ER/PR status, and residual disease plus the adjuvant plan. Missing fields should be marked unknown, not guessed.

Older patient-facing risk-group decoders built from 2021 guidance and FIGO 2009 staging are now too easy to misuse. The 2024 BGCS/BMS HRT recommendations still define their risk groups through the 2021 framework, while the 2025 ESGO update integrates FIGO 2023, molecular classification, pathological extension, and LVSI. The 2026 FIGO menopause position paper then uses a simpler stage/grade/histology split for HRT eligibility. Your oncologist may need to translate among those frameworks before applying the guidance. A static table that encourages a survivor to self-assign a risk group can be both obsolete and falsely precise.

Use this instead:

Decision fact	What to copy from the record	Why it changes the conversation
1. Exact diagnosis and histology	Endometrioid, serous, clear cell, carcinosarcoma, leiomyosarcoma, endometrial stromal sarcoma, mixed, other	Separates the evidence population from diseases where HRT is avoided or unstudied
2. FIGO stage and staging version	The stage plus whether it was assigned under FIGO 2009 or FIGO 2023	The same-looking stage label can sit inside a newer molecular/pathological framework
3. Grade	Low grade or high grade; exact FIGO grade if reported	Higher grade generally raises recurrence risk and changes the evidence zone
4. Myometrial invasion	None, less than half, half or more, or the exact pathology wording	Depth of invasion helps define pathological risk
5. LVSI	None, focal, or substantial lymphovascular space invasion	Substantial LVSI can raise risk even when the stage sounds early
6. Molecular class	POLE-mutated, mismatch-repair deficient (MMRd), no specific molecular profile (NSMP), or p53-abnormal	Current risk grouping increasingly incorporates molecular biology
7. Estrogen and progesterone receptors	ER positive/negative/unknown; PR positive/negative/unknown	BGCS/BMS separates ER/PR-negative high-risk disease from receptor-expressing high-risk disease; high-intermediate disease is already in the individualized zone
8. Residual disease and treatment plan	No residual disease versus residual/active disease; radiation, chemotherapy, endocrine therapy, surveillance, or palliative intent	HRT evidence is concentrated in women treated surgically with no known active disease

Two warnings belong beside that table.

First: this is a record-extraction tool, not a self-staging tool. Copy the facts. Ask the gynecologic oncologist to translate them into the current risk group.

Second: a favorable molecular class is not an HRT permission slip. Molecular classification improves cancer prognosis and treatment planning. It has not been validated as a stand-alone test of hormone-therapy safety after endometrial cancer.

Micro-commitment: Open your patient portal now and download the final surgical pathology report, operative note, and last oncology note. Put those three files in one folder before you ask another clinician about HRT. That one action changes the quality of the next appointment.

What does guidance say for each risk zone?

Answer: The two newest specialist frameworks agree on the lowest-risk, fully treated group and diverge at the high-risk boundary. BGCS/BMS 2024 preserves an individualized unknown zone for high-intermediate and ER/PR-negative high-risk disease. FIGO 2026 is more conservative, treating stage III–IV, grade 3, and non-endometrioid disease as contraindicated or strongly discouraged for systemic MHT.

Situation	BGCS/BMS 2024	FIGO 2026	Practical read
Selected stage I–II, grade 1–2 endometrioid disease after definitive surgery, with no residual or recurrent disease	This usually sits inside the low/intermediate group where advantages and disadvantages should be discussed (Grade B)	Systemic MHT may be considered; local vaginal estrogen acceptable; OCEBM level 2	This is the clearest overlap between current sources
High-intermediate disease, or high-risk disease with ER- and PR-negative tumors	Individualize; risk is unknown (Grade D)	Stage III–IV, grade 3, and non-endometrioid disease are classed as contraindicated for systemic MHT in the eligibility table and strongly discouraged in the text	The sources diverge; specialist-only, never online permission
High risk, advanced or metastatic, receptor expressing	Systemic HRT not recommended (Grade D)	High-risk systemic MHT contraindicated or strongly discouraged	No routine systemic route
Low-grade endometrial stromal sarcoma	Avoid unless the individual benefit outweighs risk (Grade C)	Systemic MHT and local vaginal estrogen contraindicated	No routine hormonal route
Uterine leiomyosarcoma	Avoid; only narrowly consider after alternatives fail and specialist review (Grades C/D)	Generally avoid systemic MHT; local vaginal estrogen only with caution and multidisciplinary review	Specialist-only

Three points stop this table being misused.

The stricter line matters. A woman with grade 3 or non-endometrioid disease should not use the BGCS/BMS “unknown” category as permission to ignore FIGO's more conservative 2026 position. The practical outcome is multidisciplinary review, not self-selection.

ER/PR negative is not a green light. Under BGCS/BMS it moves some high-risk disease from “not recommended because receptor-expressing” into “unknown and individualized.” Unknown is not permission.

Palliative care is not a contradiction. BGCS/BMS separately allows quality of life to justify an individualized discussion in advanced disease with palliative intent. FIGO's eligibility table does not create a separate palliative exception. That is a goals-of-care decision, not evidence that HRT is oncologically safe in advanced disease.

What did the FDA labels change in February 2026?

Answer: On February 12, 2026, the FDA approved labeling changes for six menopause hormone products. Cardiovascular disease, breast cancer, and probable dementia were removed from boxed warnings. Divigel retained a boxed warning focused on unopposed estrogen and endometrial cancer in women with a uterus. Estring now has no boxed warning.

This was a real shift, and it matters. It also does not answer the recurrence question by itself.

The current Divigel box is narrowly titled around endometrial cancer with unopposed estrogen in women with a uterus. Its recent-major-changes log records the removal of cardiovascular, breast-cancer, and probable-dementia material from the box in February 2026.

Three risks left the FDA's most prominent warning on those products. Endometrial cancer stayed on Divigel.

The current Estring label has no boxed warning. Estring is a low-dose vaginal ring that releases approximately 7.5 micrograms of estradiol per day.

What the label chronology actually shows

Here is the correction that matters: the February 2026 revision did not newly delete the words “known or suspected” from Divigel's estrogen-dependent-neoplasia contraindication. The April 2025 Divigel label already used the wording “estrogen-dependent neoplasia.” February 2026 changed the boxed warning and other sections, but it did not create that wording.

That chronology does not kill the useful finding. It makes the finding honest:

• The FDA's 2026 action materially changed the prominence and scope of menopause-HRT warnings.
• Divigel's retained box is explicitly about a woman with a uterus using unopposed estrogen.
• Estring lost its boxed warning.
• Neither label is a recurrence guideline for a survivor after hysterectomy.

The clean takeaway is not “the FDA quietly cleared HRT after endometrial cancer.” It did not. The takeaway is that prevention warnings, product contraindications, and survivor recurrence guidance answer different questions.

Do the current FDA contraindications cover a past endometrial cancer?

Answer: The labels do not give a survivor-specific rule. Divigel lists “estrogen-dependent neoplasia”; Estring lists “known or suspected estrogen-dependent neoplasia.” Neither phrase defines whether a fully treated endometrial cancer with no current disease remains a contraindication forever. That ambiguity belongs with a prescriber and oncologist, not a website inference.

Here is the current side-by-side record:

Label element	Divigel — systemic estradiol gel	Estring — low-dose vaginal estradiol ring
Current revision	February 2026	February 2026
Boxed warning	Endometrial cancer with unopposed estrogen in women with a uterus	None
Breast-cancer contraindication	Current or history of breast cancer	Not listed in the current contraindications
Estrogen-dependent-neoplasia wording	“Estrogen-dependent neoplasia”	“Known or suspected estrogen-dependent neoplasia”
DVT/PE and arterial-clot history	Explicitly includes active disease or history	Explicitly includes active disease or history
Total listed contraindication bullets	Eight	Seven
Does the professional label define a treated past endometrial cancer?	No	No

Three things matter.

One: absence of “history” is not proof of permission. A clinician may reasonably treat a prior hormone-sensitive cancer as falling within the contraindication. Another may distinguish fully treated early-stage disease from a current neoplasm by using specialty guidance. The label does not resolve that clinical judgment.

Two: route and exposure matter, but lower exposure is not zero exposure. Estring is not interchangeable with systemic Divigel, and neither should be treated as interchangeable with every cream, tablet, insert, or compounded preparation.

Three: the patient leaflet invites the conversation. Estring's current patient information tells women who have or had an estrogen-dependent cancer to talk with their healthcare provider about whether to use it. That is not an approval. It is direct evidence that asking the question is not reckless.

This is the emotional permission the labels can honestly give you: you are allowed to ask. They cannot give you the answer.

What did the only randomized trial find?

Answer: The only randomized trial assigned 1,236 women with stage I–II endometrial cancer to estrogen or placebo after surgery. Recurrence was 2.3% with estrogen and 1.9% with placebo. The trial closed early, follow-up was about three years, and Cochrane rated the evidence very low certainty. That is no clear harm signal, not proof of safety.

The Gynecologic Oncology Group trial published by Barakat and colleagues remains the only randomized recurrence test in this population. The estrogen arm used oral conjugated estrogen 0.625 mg daily, so it did not directly test patches, gels, low-dose vaginal products, or every regimen used today.

Outcome	Estrogen (n=618)	Placebo (n=618)
Recurrence	14 women (2.3%)	12 women (1.9%)
New cancer at another site	8 (1.3%)	10 (1.6%)
Death from endometrial cancer	5 (0.8%)	4 (0.6%)
Alive with no evidence of disease at the reported follow-up point	94.3%	95.6%

Cochrane calculated a recurrence risk ratio of 1.17, with a 95% confidence interval from 0.54 to 2.50. In plain language, the trial was compatible with substantially less recurrence, no meaningful difference, or substantially more recurrence. It was too imprecise to settle the question.

The limitations are not small:

• Enrollment stopped before the planned sample was reached after the Women's Health Initiative disrupted recruitment.
• Median follow-up was 35.7 months.
• Only 251 of 618 women in the estrogen arm — 41.1% — remained compliant for the entire planned treatment period.
• The participants were overwhelmingly selected stage I–II patients; the trial does not answer high-risk, advanced, metastatic, or sarcoma cases.
• The study did not establish overall-survival benefit, long-term recurrence safety, or the best formulation, route, dose, or start time.

Cochrane's verdict was very-low-certainty evidence. That is the floor of its certainty scale.

The racial subgroup signal should not be buried

A post-hoc subgroup result from the randomized-trial evidence, summarized in the later meta-analysis, reported a concerning recurrence signal among Black American women using continuous estrogen therapy: hazard ratio 7.58, with a very wide 95% confidence interval of 1.96 to 29.31. It came from an already underpowered evidence base, so it cannot predict an individual woman's outcome. It also cannot be ethically erased because it complicates the reassuring headline.

The right response is not to turn one unstable subgroup estimate into a race-based prohibition. It is to admit that the evidence base did not protect every subgroup equally well and that better data are overdue.

What do the larger studies add?

Answer: Observational studies involving thousands of survivors have generally not shown higher recurrence among HRT users, and pooled odds sometimes look protective. That apparent protection is not credible as a drug effect because clinicians preferentially selected younger, lower-risk women for HRT. The useful signal is absence of consistent harm in selected early-stage populations — not cancer prevention.

Evidence set	Population	Main result	What stops it proving safety
Londero 2021 meta-analysis	1,801 HRT users and 6,015 controls across one randomized and seven observational studies	Disease-free-survival HR 0.90 (0.28–2.87); pooled recurrence OR 0.63 (0.48–0.83)	Predominantly observational; treatment selection and overlapping cohorts can make HRT look protective
Cochrane randomized evidence	1,236 women in one early-stage trial	RR 1.17 (0.54–2.50)	Early closure, short follow-up, low adherence, very low certainty
Earlier cohort and case-control studies	Mostly stage I–II, often younger and lower-risk women	No consistent recurrence increase	Nonrandomized and not representative of high-risk disease

This is confounding by selection in ordinary language: doctors chose the women they felt safest treating, and those women were more likely to do well regardless. The honest conclusion is narrower than “HRT is safe after endometrial cancer.”

It is this:

Across selected, mainly early-stage survivors, the available studies have not produced a consistent recurrence-harm signal. The evidence becomes weak or absent when the woman does not resemble that selected population.

That is meaningfully reassuring for the right reader. It is close to useless for the wrong one.

Does progesterone change endometrial-cancer risk?

Answer: Continuous combined estrogen plus progestogen reduced the incidence of a first endometrial cancer in the Women's Health Initiative. That explains the biology of protecting an intact uterus. It does not prove that progesterone prevents recurrence after hysterectomy, and no survivor trial has directly compared estrogen-only with combined HRT.

In the WHI randomized trial, 16,608 postmenopausal women with a uterus received continuous combined conjugated estrogen plus medroxyprogesterone or placebo. Over extended follow-up, endometrial cancer occurred at 0.06% per year with combined therapy versus 0.10% per year with placebo, hazard ratio 0.65.

That finding surprises people because the cultural memory of WHI is simply “hormones cause cancer.” For incident endometrial cancer under continuous combined therapy, the result went the other way.

The fence around it is non-negotiable:

• These women had not been treated for endometrial cancer.
• They still had a uterus.
• The result concerns prevention of a first cancer, not recurrence after cancer treatment.
• It used one specific oral regimen, not every estrogen/progestogen combination.

BGCS/BMS says the biology could be extrapolated when considering continuous combined HRT after endometrial cancer, especially in difficult higher-risk quality-of-life cases. The same guideline immediately states that there are no direct data comparing combined HRT with estrogen-only HRT in endometrial-cancer survivors.

So progesterone is a legitimate prescriber question. It is not cancer insurance.

Is vaginal estrogen different after endometrial cancer?

Answer: Yes. Low-dose vaginal estrogen targets vaginal and urinary symptoms with much lower systemic exposure than systemic HRT. BGCS/BMS considers it safe for the majority of women after gynecological cancer, including many who are not candidates for systemic HRT. Product, dose, formulation, healing, and cancer type still matter.

FIGO 2026 adds a disease-specific boundary: local vaginal estrogen is acceptable for selected stage I–II, grade 1–2 endometrioid disease; use with caution for stage III–IV, grade 3, non-endometrioid disease and uterine leiomyosarcoma; and contraindicated after low-grade endometrial stromal sarcoma.

If the main problem is vaginal dryness, burning, painful sex, recurrent urinary symptoms, or tissue fragility — genitourinary syndrome of menopause, or GSM — this may be the most important section on the page.

How different is the exposure?

The BGCS/BMS guideline makes the scale memorable: the total annual dose from current low-dose vaginal products is roughly comparable to a single oral systemic dose, and systemic absorption is minimal. That is a class-level summary, not a promise that every vaginal product behaves identically.

The current Estring label gives product-specific numbers:

• The ring releases approximately 7.5 micrograms of estradiol per day.
• Mean serum estradiol values were 7.8, 7.0, 7.0, and 8.1 pg/mL at weeks 12, 24, 36, and 48.
• Approximately 8% of the released daily dose was systemically absorbed unchanged.
• After subtracting each woman's baseline estradiol, the mean added level at week 12 was 0.4 pg/mL.

That is low exposure. It is not no exposure.

The product comparison buried in the Estring label

In a 12-week U.S. study of women who still had a uterus, the label reports endometrial overstimulation in:

• 0 of 58 Estring users
• 4 of 35 users of conjugated-estrogens vaginal cream

Both products were vaginal. They did not produce the same finding in that small study.

This does not prove that Estring prevents recurrence after endometrial cancer. It proves something more practical: “vaginal estrogen” is not a complete product description. Formulation and dose deserve to be discussed by name.

What did the 2026 survivor study find?

The newest study we identified by the August 6, 2026 verification date was published online in March 2026 and in the journal's August issue. It used the U.S. TriNetX network:

• 68 healthcare organizations
• Women aged 18–51 diagnosed with endometrial cancer from November 2005 through December 2023
• 1,412 vaginal-estrogen users and 23,859 nonusers before matching
• Two matched groups of 1,412
• Mean vaginal-estrogen treatment duration 1.88 years
• Proxy recurrence outcome: 53 versus 54 events, hazard ratio 0.87 (95% CI 0.60–1.27)

That is reassuring. It is not settled.

The limitations belong beside the result:

• Stage was missing often enough that the researchers could not reliably stratify results by stage.
• There is no direct billing code for endometrial-cancer recurrence, so the outcome was inferred from later treatment and surgery codes.
• Prescription claims do not prove the product was collected or used.
• Daily dose was unavailable.
• Some women in the comparison group may have started vaginal estrogen later.
• The treated group may have had stronger health-seeking behavior despite matching.
• The cohort was much younger than the typical U.S. uterine-cancer population.
• An average treatment duration under two years cannot settle long-term safety.

What about prasterone and ospemifene?

They are not automatic loopholes. Vaginal prasterone is converted into active androgens and/or estrogens. Ospemifene acts through estrogen receptors, and its current label lists estrogen-dependent neoplasia as a contraindication. A woman with a cancer history still needs a product-specific conversation rather than a marketing category called “non-estrogen.”

Hormone-free options include moisturizers, lubricants, pelvic-floor physical therapy, and clinician-directed dilator support. These can be used alone, while awaiting a decision, or alongside other treatment.

If dryness or painful sex is the main problem — not hot flashes — you are asking a different question with a more targeted route. Use Find My HRT Path to separate local from systemic care and compare care routes. Keep the cancer decision with oncology even if the tool returns an online option. For product forms, dosing questions, and general GSM care, see The HRT Index's vaginal estrogen guide.

How long do you have to wait before starting HRT?

Answer: There is no evidence-based universal number of months. The current cancer-specific guidance uses a pathology gate: final histology, complete staging, residual-disease status, and the plan for any additional treatment should be known before a complex HRT decision. The question is what information or treatment milestone is pending — not which internet countdown sounds authoritative.

You will see “wait 6 months,” “wait 12 months,” and “wait 24 months” repeated with confidence. We did not find a cancer-specific guideline establishing one universal interval.

BGCS/BMS says that when the decision is complex or controversial, it should wait until:

• Histology is known.
• Full staging is complete.
• A plan for additional treatment has been made.
• Final pathology is available when the cancer may be hormone sensitive.

For vaginal estrogen, the guideline says treatment can begin once the vagina has healed after surgery and that no arbitrary time limit should be placed on duration. Your surgeon decides when healing is adequate.

For systemic HRT, the guideline also rejects arbitrary duration limits. That does not mean indefinite treatment without review. It means duration should follow the woman's age, symptoms, risks, goals, and ongoing reassessment rather than a universal stop date.

Better questions than “how many months?”

1. Which pathology result are we waiting for?
2. Is there residual or active disease?
3. Does planned radiation, chemotherapy, immunotherapy, or endocrine therapy change the answer?
4. Would low-dose vaginal treatment be evaluated differently from systemic treatment?
5. What can we treat now while the cancer decision remains open?
6. Who will reassess the plan, and when?

The waiting is the hardest part when it comes with no plan. Use Find My HRT Path to identify whether your symptoms are local or systemic and which care route fits — while keeping the oncology decision where it belongs.

Do you need estrogen alone or estrogen with progesterone?

Answer: After a total hysterectomy, a progestogen is usually not needed because there is no uterine lining to protect. After endometrial cancer, no direct trial has shown that adding progesterone prevents recurrence. A subtotal hysterectomy, residual endometriosis, retained uterus, or a cancer-specific concern can change the prescriber's decision.

The ordinary menopause rule is simple:

• Uterus present: systemic estrogen normally requires a progestogen for endometrial protection.
• Total hysterectomy: estrogen-only treatment is usually considered.

Cancer history makes the second line less automatic, not because progesterone has proved recurrence protection, but because the prescriber may be weighing uncertain biology, the original pathology, and the woman's other risks.

Two details need explicit confirmation:

• Was the hysterectomy total or supracervical/subtotal? With a supracervical procedure, the cervix remains and residual endometrial tissue may be possible.
• Is there a history of endometriosis? Residual endometriosis is a recognized exception to the casual “no uterus, no progestogen” shortcut.

The strongest sentence here is also the simplest: nobody should sell progesterone to an endometrial-cancer survivor as proven recurrence protection. The study does not exist.

FDA-approved and compounded products are not interchangeable

FDA-approved products have a reviewed label, standardized manufacturing requirements, and product-specific safety and pharmacokinetic data. Compounded finished drugs are not FDA-approved, and the FDA does not review them before marketing for safety, effectiveness, or manufacturing quality in the same way.

The BGCS/BMS guideline advises against compounded “bioidentical” preparations because they follow different regulatory pathways and create concerns about purity, safety, efficacy, and endometrial protection.

That does not mean every compounded prescription is automatically adulterated or never clinically justified. It means a compounded product cannot borrow the evidence or label of an FDA-approved product. On a page where product-specific absorption and endometrial data are central, that gap matters more, not less.

What if you still have your uterus?

Answer: Almost all recurrence evidence on this page comes from women treated surgically, usually with hysterectomy. If you had fertility-sparing treatment and still have a uterus, the randomized trial does not describe you. Menopause treatment, endometrial protection, cancer therapy, fertility goals, and surveillance have to be managed as one oncology plan.

Selected younger patients with early, low-grade endometrioid carcinoma or a precursor lesion may receive fertility-sparing progestin-based treatment instead of immediate hysterectomy. That route involves repeated endometrial sampling and a cancer-treatment dose or device chosen for oncologic control.

The ordinary menopause algorithm — “add progesterone if the uterus remains” — is not enough. In this setting, progestin may already be part of active cancer treatment, and adding estrogen can affect a surveillance plan that depends on repeated tissue assessment.

Questions for the treating team:

1. Is there residual hyperplasia or carcinoma on the latest sampling?
2. Is progestin part of the cancer treatment now, and at what dose or device?
3. What is the surveillance schedule?
4. Would any estrogen exposure change that schedule or the interpretation of bleeding?
5. Is pregnancy still a goal?
6. Which non-hormonal or local measures can treat symptoms within the oncologic plan?

There is no responsible form-based online route for clearing systemic HRT in this situation. That is not a sales objection to overcome. It is the answer.

When is systemic HRT not recommended?

Answer: Systemic HRT is not the routine route for active or recurrent disease, receptor-expressing high-risk/advanced/metastatic disease, advanced-stage disease under the U.S. SGO statement, or uterine sarcoma. Standard drug contraindications still apply. New unexplained bleeding is a report-now symptom, not an online eligibility question.

We would rather make this section too clear than too gentle.

Active, recurrent, or incompletely evaluated disease

The oncology plan controls. A menopause platform cannot determine recurrence status from an intake form.

High-risk, advanced, or metastatic receptor-expressing endometrial cancer

BGCS/BMS does not recommend systemic HRT. Endocrine treatment may be used against hormone-responsive recurrent disease; adding estrogen can run against that strategy.

Advanced-stage disease under U.S. guidance

SGO states that there are no data supporting hormone therapy in stage III–IV endometrial cancer and does not recommend it. BGCS/BMS adds individualized receptor-status and palliative-intent nuance, but it does not turn advanced disease into an ordinary telehealth-HRT case.

Uterine sarcoma

Avoid HRT after leiomyosarcoma or endometrial stromal sarcoma except narrowly individualized specialist decisions described above. The evidence from early-stage endometrial carcinoma does not apply.

Endometrial cancer diagnosed while taking tamoxifen

Tamoxifen raises endometrial-cancer risk. The cancer-specific guideline says the patient should be referred back to the breast-oncology team to consider the endocrine-treatment plan. Do not stop tamoxifen on the basis of a webpage. Contact the breast-oncology team promptly so that team can decide whether to switch, stop, or continue treatment.

Standard non-cancer contraindications and warnings

The exact list depends on the product and route, but active or prior thromboembolic disease, certain arterial events, liver disease, unexplained genital bleeding, and product-specific cancer contraindications can matter. The prescriber must use the current label for the exact product rather than a generic HRT checklist.

New vaginal bleeding or spotting

Report it promptly. Do not assign it to menopause, vaginal tissue, HRT, or “probably nothing” before your cancer team knows.

If you are in this section, the next section is not a consolation prize. It is the treatment plan that should have been offered with the “no.”

If HRT is off the table, what actually works?

Answer: Several non-hormonal treatments have randomized evidence for vasomotor symptoms, although none is as effective as estrogen-based therapy overall. Evidence-backed routes include CBT, selected SSRIs/SNRIs, gabapentin or pregabalin, oxybutynin, and neurokinin-receptor antagonists. Drug interactions, liver monitoring, sedation, seizure history, pregnancy potential, and other conditions change the fit.

The honest frame from BGCS/BMS is that non-hormonal therapies can reduce the impact of menopause symptoms but none is as effective as estrogen-based therapy. That is not a reason to dismiss them. It is a reason to match the treatment to the symptom and stop pretending every alternative works equally well.

Option	Evidence position in BGCS/BMS	Practical decision point
Cognitive behavioral therapy	Grade B	Can reduce how disruptive hot flashes feel and help sleep, mood, and anxiety without a drug interaction
SSRIs/SNRIs	Grade A	Choice depends on other medications; tamoxifen interactions matter
Gabapentin or pregabalin	Grade A	Can help vasomotor symptoms and sleep; sedation and dizziness can be limiting
Neurokinin-receptor antagonists	Grade A class recommendation	Effective non-hormonal prescription route; each product has its own liver, interaction, pregnancy, and neurologic precautions
Oxybutynin	Grade C	Can reduce sweating/hot flashes; anticholinergic adverse effects matter, especially with age or cognitive risk

If you take tamoxifen, the antidepressant choice is not casual

BGCS/BMS advises avoiding paroxetine, sertraline, and fluoxetine with tamoxifen because of CYP-mediated interaction concerns. It identifies venlafaxine, escitalopram, and citalopram as options that can be offered. Your oncology and prescribing teams should check the full medication list rather than treating “an antidepressant” as one interchangeable class.

Fezolinetant (Veozah)

Fezolinetant is an FDA-approved NK3-receptor antagonist for moderate-to-severe vasomotor symptoms. In December 2024, its FDA-approved label added a boxed warning for hepatotoxicity.

The current label requires:

• Baseline hepatic laboratory testing.
• Monthly testing for the first three months.
• Testing again at months six and nine.
• Immediate evaluation if symptoms suggest liver injury.

The label also lists known cirrhosis, severe renal impairment or end-stage renal disease, and concomitant CYP1A2 inhibitors as contraindications. This is a non-hormonal drug, not a no-monitoring drug.

Elinzanetant (Lynkuet)

The FDA approved Lynkuet on October 24, 2025. It blocks NK1 and NK3 receptors and is approved for moderate-to-severe vasomotor symptoms due to menopause.

Its current label requires liver testing before treatment and again three months after initiation, with additional testing if symptoms arise. It warns about daytime impairment and somnolence, liver-enzyme elevations, pregnancy loss, and seizure risk in susceptible patients. Pregnancy is a formal contraindication. The label says to avoid strong CYP3A4 inhibitors and inducers; that interaction warning should not be rewritten as a different formal contraindication.

Neither Veozah nor Lynkuet was tested as proof of oncologic safety after endometrial cancer. They are non-hormonal treatments for vasomotor symptoms, which is why they can be considered when estrogen is not the route.

Where not to spend hope as if it were evidence

The guideline does not support treating exercise alone as a hot-flash therapy, even though exercise remains valuable for overall health and bone protection. Acupuncture has generally not beaten sham acupuncture in systematic reviews. Phytoestrogens are discouraged after hormone-sensitive tumors. St. John's wort is discouraged because of serious drug interactions.

“Natural” does not mean interaction-free, cancer-neutral, or tested in survivors.

Do not let the hormone decision erase the bone plan

Early or abrupt loss of ovarian function raises bone-loss risk, and pelvic radiotherapy can add to it. A complete plan may include baseline or follow-up bone-density testing, adequate calcium and vitamin D based on diet and clinical need, weight-bearing and resistance exercise, smoking cessation, alcohol review, and osteoporosis medication when indicated.

This applies whether the answer to systemic HRT is yes, no, or not yet.

The minimum acceptable outcome of a “no HRT” appointment is not “live with it.” It is a named treatment for the symptom that hurts most, a monitoring plan, and a date to review whether it worked. The HRT Index's non-hormonal options guide covers the broader medication and symptom pathways.

Why do reputable sources give different answers?

Answer: They are often answering different questions. FDA boxed warnings address product risks in broad populations. Patient pages default to simple caution without pathology. Cancer guidelines stratify by disease risk. Studies report outcomes in selected populations. When those questions are collapsed into one sentence, the answers appear to contradict each other.

Source	The question it is actually answering	Why the wording differs
FDA boxed warning	What prominent product risk must be communicated, including unopposed estrogen causing endometrial cancer in a woman with a uterus?	A drug label is not a recurrence guideline for one cancer-survivor subgroup
FDA contraindication section	Which conditions make use of this exact product inappropriate under the label?	Product-specific wording can be broad and may not define a fully treated prior cancer
General patient page	What is the safest simple message for a reader whose pathology is unknown?	It often defaults to “avoid” because it cannot stratify risk
BGCS/BMS, FIGO, or SGO guidance	How should clinicians think about HRT after specific gynecological cancers and stages/risk groups?	Publication dates, classification systems, and evidence judgments differ; the high-risk boundaries do not align perfectly
Randomized or observational study	What happened in one defined population under one design?	A study result is not a universal clinical rule
Forum, podcast, or testimonial	What happened to one person or what someone remembers hearing?	Useful for language and lived experience, not recurrence evidence

Some of the disagreement is real, not merely apparent. BGCS/BMS preserves an unknown individualized zone for high-intermediate and ER/PR-negative high-risk disease; FIGO 2026 takes a stricter position on stage III–IV, grade 3, and non-endometrioid disease. This page does not hide that gap or turn it into reader permission.

There is another source of friction: the evidence aged while cancer classification changed. The randomized trial enrolled women under older staging and without today's routine molecular risk framework. Current oncology guidance incorporates FIGO 2023 stage, molecular class, pathological extension, and LVSI.

That is why “early stage” can be directionally useful and still insufficient. A stage label from twenty years ago cannot carry every fact a 2026 oncologist now has.

What does untreated surgical menopause cost?

Answer: Abrupt ovarian-function loss can cause more intense symptoms than natural menopause and can affect bone, sexual, urinary, sleep, mood, and long-term health. The decision is not “risk from HRT versus zero risk from no HRT.” It is a comparison between cancer-related uncertainty, ordinary medication risks, symptom burden, and the consequences of untreated early menopause.

The SGO statement notes that about one-quarter of endometrial cancers are diagnosed before menopause. Many younger women undergo hysterectomy with removal of both ovaries, although ovarian conservation can be considered in selected oncology cases under current guidance.

For a woman in her thirties or forties, abrupt menopause can mean:

• Severe hot flashes and night sweats.
• Insomnia and fatigue.
• Vaginal and urinary tissue changes.
• Sexual pain or loss of function.
• Accelerated bone loss.
• Fertility loss.
• Mood and cognitive symptoms that can be intensified by cancer treatment and recovery.

The BGCS/BMS guideline lists osteoporosis, cardiovascular consequences, bladder dysfunction, and neurocognitive concerns among the health effects of premature ovarian insufficiency. It also emphasizes that cancer treatments can worsen sexual, bladder, and pelvic-bone problems.

We include this for one reason: the conversation is often framed as HRT risk versus safety. That frame makes untreated surgical menopause disappear.

A good decision weighs both sides without using either as pressure. Some women in the first zone may reasonably discuss HRT. Some women in the third zone will not be candidates. The second group deserves a serious non-hormonal plan, GSM plan, bone plan, and follow-up — not a thinner version of care.

What should you ask your gynecologic oncologist?

Answer: Ask for a written, pathology-based decision covering systemic HRT, low-dose vaginal estrogen, current uncertainties, non-hormonal treatment, monitoring, and who owns follow-up. The goal is not to force a yes. It is to stop receiving a context-free no that every later clinician repeats without knowing why.

Print this section or copy it into the portal message.

About the cancer

1. What was my exact diagnosis and histology? Was it endometrial carcinoma or a uterine sarcoma?
2. Which FIGO staging system was used, and what was the final stage?
3. What was the grade and depth of myometrial invasion?
4. Was LVSI absent, focal, or substantial?
5. Was molecular testing performed? If so, was the tumor POLE-mutated, MMR-deficient, NSMP, or p53-abnormal?
6. Were estrogen and progesterone receptors tested? Please mark them positive, negative, or unknown rather than assuming.
7. Was there residual disease after surgery?
8. Which current risk group do those facts place me in?
9. Does radiation, chemotherapy, immunotherapy, or endocrine therapy change the menopause plan?

About hormone therapy

1. Does current guidance support discussing systemic HRT in my case?
2. What specific fact makes your answer yes, no, or not yet?
3. Does your answer change for low-dose vaginal estrogen?
4. Which vaginal product, dose, and formulation would you consider, and why?
5. What are we waiting for — a pathology result, completion of treatment, healing, or a surveillance milestone?
6. If I had a total hysterectomy, is there a cancer-specific or endometriosis-related reason to add a progestogen?
7. What symptom or finding would make us stop or reassess treatment?

About the plan if HRT is not the route

1. Which non-hormonal treatment best matches my worst symptom?
2. Does it interact with tamoxifen or any other cancer medication?
3. What is my bone-health plan?
4. What is the treatment plan for vaginal and urinary symptoms?
5. When will we review whether the first treatment worked?
6. Who manages this after oncology — your clinic, primary care, gynecology, or a menopause specialist?

The one request worth more than the whole list

Ask for a short written note that says:

• Exact diagnosis and treatment status.
• Whether systemic HRT may be discussed, is not recommended, or remains undecided.
• Whether low-dose vaginal estrogen may be considered.
• Any product, route, dose, or monitoring restrictions.
• Who retains oncology oversight.

Most repeat refusals happen verbally, downstream, by a clinician who does not want to reinterpret a cancer history. A clear oncology note can end that loop.

Walk in with the record, not a phone full of tabs. Find My HRT Path can help you identify the symptom route and care model; the pathology questions above are what make the specialist visit decisive.

Where can you get menopause care after oncology clears you?

Answer: Oncology decides whether HRT can be considered. A menopause clinician can manage symptoms and ongoing prescribing after that decision is documented. The best telehealth fit is a service that reviews records, offers hormonal and non-hormonal care, separates FDA-approved from compounded products, publishes real prices, and knows when to refer out.

The sequence matters.

Step one is oncology. A platform that approves HRT from a basic questionnaire without understanding the exact diagnosis, pathology, current disease status, and oncology plan is skipping the safety question.

Step two is the care gap. The oncologist may clear discussion but not provide long-term menopause management. Primary care may still be unwilling to prescribe. That is where a menopause-focused clinician can be useful.

Applying The HRT Index Verification Standard, a service for this reader should meet the five pillars in this exact order:

1. Clinical legitimacy — licensed clinicians, cancer-history intake, and willingness to coordinate with oncology.
2. Care quality — real visits, record review, follow-up, local testing referrals, and a clear escalation route.
3. Medication fit — FDA-approved options clearly separated from compounded products, plus a real non-hormonal pathway.
4. Price transparency — published self-pay pricing and plan-specific insurance language without fake “starting at” math.
5. Access — state availability and truthful Medicare, Medicaid, and commercial-insurance rules.

The most defensible follow-on telehealth option we verified

Among the services checked for this page, Midi Health had the clearest documented follow-on cancer-survivorship pathway for a commercially insured or self-pay patient after oncology clearance. That is an editorial fit conclusion based on the provider-stated facts below. It is not a claim that Midi has a published endometrial-cancer clearance protocol or can determine cancer safety from an online intake.

Provider-stated facts verified against Midi's public pages on August 6, 2026 — not independently tested patient outcomes:

Decision point	Provider-stated fact	Source check	Practical meaning
Availability	Virtual care in all 50 states	Published on its cancer-survivorship page	State access is broad; clinician licensure still applies to the visit
Visit model	Virtual clinician visit	First visits are described as about 30 minutes	More than an asynchronous questionnaire
Cancer-survivorship care	Hormonal and non-hormonal treatment options for eligible patients	Cancer page lists vaginal estrogen, HRT for eligible patients, fezolinetant, gabapentin, SSRIs, and SNRIs	It has a survivorship pathway, but the public page is strongest on breast-cancer examples rather than a published endometrial-cancer protocol
Commercial insurance	In-network with most PPO plans	Coverage varies; deductible, coinsurance, and copay may apply	Check the exact plan before booking; “in network” is not a promised copay
Self-pay	$250 initial visit; $150 continued-care visit	Prices shown on the cancer page	Visit fees are published; medications, labs, and outside services may be separate
Medicare	Not covered by Medicare or Medicare-related plans	Medicare beneficiaries may use Midi as self-pay but cannot submit Midi-related claims	Medicare is a self-pay route, not an insurance-billed route
Medicaid/Medi-Cal	Not enrolled	Midi says it cannot treat Medicaid or Medi-Cal patients even as self-pay	This is a hard access exclusion
In-person testing	Refers to local facilities; generally uses Labcorp for bloodwork	Published in the cancer-page FAQ	Telehealth does not eliminate local testing or imaging needs
Appointment changes	Cancel or reschedule in the Midi Portal with at least 24 hours' notice	Midi says shorter notice may trigger a cancellation fee; its public help article does not publish the fee amount	Confirm the exact late-cancellation fee before booking rather than assuming it is $0

The damaging admission

Midi is not a universal answer. The public survivorship page is built largely around breast-cancer scenarios, not a published endometrial-cancer clearance protocol. It does not bill Medicare. It cannot treat Medicaid or Medi-Cal patients even if they offer to self-pay. And the median age at U.S. uterine-cancer diagnosis is 64, so those public-program exclusions matter to a large share of this audience.

If you use Medicare, Midi permits self-pay, but you cannot submit its visits, medications, or associated services to Medicare. If you use Medicaid or Medi-Cal, Midi is the wrong door entirely. Ask the cancer center for a survivorship clinic, hospital menopause program, gynecology service, or in-person menopause specialist that participates in your coverage.

For a younger survivor with commercial PPO coverage or the ability to self-pay, the trade-off can still work: all-state virtual access, menopause-focused visits, non-hormonal options, and local lab coordination after oncology has documented the cancer decision.

Affiliate disclosure: The HRT Index has an affiliate relationship with Midi and may earn a commission when a qualifying tracked link is used. The link below goes to Midi's official cancer-survivorship page so you can verify the current facts directly. The relationship does not change the fit limits, price verification, or who we tell not to use Midi.

If oncology has already documented that menopause treatment can be managed outside the cancer clinic: check Midi's current cancer-survivorship care, coverage, and self-pay terms. Bring the oncology note to the first visit.

Two affiliate relationships that do not change this page's recommendation

The HRT Index also has affiliate relationships with Winona and Inner Balance/Oestra. That does not make a compounded systemic option from either service the right evidence match here.

Winona's current HRT page separates its FDA-approved estrogen patches, estrogen tablets, and progesterone capsules from its compounded estrogen/progesterone body creams, which are not FDA-approved. Inner Balance describes Oestra as a compounded estradiol/progesterone cream designed for systemic absorption.

We are not recommending a compounded systemic product to resolve this reader's question. Compounded finished drugs are not FDA-approved, and they cannot borrow Estring's absorption data, Divigel's label, or the recurrence evidence attached to studied regimens. Oestra is not the same category as low-dose local Estring, even though both can involve vaginal administration.

The correct decision order is oncology clearance first, formulation second, provider third, affiliate economics nowhere in the clinical reasoning.

How did The HRT Index research this page?

Answer: We used primary guidance, current FDA labels, peer-reviewed studies, and dated provider pages. Every label chronology, risk framework, drug contraindication, insurance rule, and tool promise was checked against its source before publication. Where the evidence itself is uncertain, the page says so.

The HRT Index Verification Standard is the documented process used to read published claims at the source, separate FDA-approved from compounded medication, verify commercial facts on provider pages, and re-check on a fixed schedule. For this page, it covered:

• Cancer-specific guideline wording and evidence grades, including the July 2026 FIGO position paper.
• Current FIGO 2023/molecular-risk context and the places where HRT frameworks do not align.
• FDA label revision dates, boxed warnings, contraindications, patient information, pharmacokinetics, and clinical-study tables.
• Randomized-trial enrollment, events, adherence, follow-up, and Cochrane certainty.
• Observational-study populations and confounding.
• Provider availability, visit prices, insurance exclusions, self-pay rules, lab logistics, and appointment-change terms.
• Whether every CTA promises something the destination actually delivers.

What we refused to do

We did not turn the February 2026 label change into survivor clearance, treat an observational protective association as proof that HRT prevents recurrence, or call compounded medication equivalent to an FDA-approved product. There is no fabricated clinical review, numeric provider score, survivor testimonial used as a safety claim, or tool deliverable the destination does not provide.

The forum fragments on this page are used only to show how refusal feels. They are not evidence that HRT is safe or unsafe.

What will need re-verification

Answer: Medical guidance, FDA labels, drug safety, provider prices, insurance rules, and tool gates can all change. The schedule below separates monthly commercial checks from quarterly evidence checks and annual epidemiology updates. The visible “Last verified” date should move only when the relevant claims have actually been rechecked.

Element	Re-check cadence	What changes the page
FDA menopause-hormone labels	Monthly	New products join the relabeling program; contraindications or boxed warnings change
BGCS/BMS, FIGO, SGO, The Menopause Society, ESGO guidance	Quarterly	New guideline, position paper, update, retraction, or formal U.S. position
Vaginal-estrogen survivor evidence	Quarterly	Longer follow-up, stage-specific analysis, new cohort, or randomized data
Veozah and Lynkuet labels	Quarterly	Safety communication, monitoring change, contraindication, or indication update
Midi pricing, insurance, public-program rules, availability, appointment-change terms, and care features	Monthly	Price, payer participation, state access, cancellation policy, or program design changes
SEER age and incidence data	Annually	New data release

Frequently asked questions

Can you take HRT after endometrial cancer?

Sometimes. The clearest overlap in current guidance is carefully selected stage I–II, grade 1–2 endometrioid carcinoma after definitive surgery with no residual or recurrent disease. BGCS/BMS also supports discussion for low/intermediate risk after hysterectomy. Higher-risk frameworks diverge: some cases are unknown and individualized under BGCS/BMS, while FIGO 2026 is more restrictive. A gynecologic oncologist has to apply the pathology.

How long after endometrial cancer can you start HRT?

There is no universal evidence-based waiting period. The meaningful gate is final histology, complete staging, residual-disease status, healing, and the plan for additional treatment. Ask what result or milestone is pending rather than assuming a fixed 6-, 12-, or 24-month rule.

Is vaginal estrogen safe after endometrial cancer?

BGCS/BMS considers vaginal estrogen safe for the majority of women after gynecological cancer, with rare exceptions. FIGO 2026 calls it acceptable in selected stage I–II, grade 1–2 endometrioid disease, cautions in higher-risk uterine categories, and contraindicates it after low-grade endometrial stromal sarcoma. A 2026 matched study found no increased short-term proxy recurrence signal, but stage and outcome limitations remain.

Does HRT increase the risk of endometrial cancer coming back?

The only randomized trial found recurrence in 2.3% of estrogen users and 1.9% of placebo users, with no statistically clear difference. It closed early, follow-up was short, adherence was low, and Cochrane rated the evidence very low certainty. The supported phrase is no clear harm signal in selected early-stage survivors, not proven safety for every survivor.

Does the type of endometrial cancer matter?

Enormously. Endometrial carcinoma and uterine sarcoma do not share the same evidence. Within carcinoma, histology, stage, grade, invasion, LVSI, molecular class, receptor status, residual disease, and treatment determine which evidence zone fits.

What if I had serous, clear-cell, or carcinosarcoma histology?

FIGO 2026 groups serous, clear-cell, and carcinosarcoma with non-endometrioid high-risk disease and treats systemic MHT as contraindicated or strongly discouraged. BGCS/BMS uses risk group and receptor status and preserves an unknown individualized zone for some ER/PR-negative high-risk disease. Either way, this is specialist-only and not an online-clearance case.

Do I need progesterone after hysterectomy?

Usually not after a total hysterectomy because there is no uterine lining to protect. No survivor trial has shown that progesterone prevents recurrence after endometrial cancer. A subtotal hysterectomy, residual endometriosis, retained uterus, or an individualized cancer concern can change the prescriber's plan.

Did the February 2026 FDA label changes clear HRT for cancer survivors?

No. The FDA removed cardiovascular, breast-cancer, and probable-dementia material from boxed warnings on six products. Divigel retained a box focused on unopposed estrogen and endometrial cancer in women with a uterus; Estring has no box. Those changes do not function as recurrence guidance after endometrial cancer.

Can a telehealth provider prescribe HRT after endometrial cancer?

A licensed telehealth clinician can prescribe when legally and clinically appropriate, but a platform should not be the first or only decision-maker for cancer safety. The responsible sequence is oncology review and written clearance or restrictions first, then ongoing menopause management by a qualified clinician.

What are the strongest non-hormonal options?

Evidence-backed options include CBT, selected SSRIs/SNRIs, gabapentin or pregabalin, oxybutynin, fezolinetant, and elinzanetant. The choice depends on the main symptom, tamoxifen or other drug interactions, liver and kidney function, sedation, pregnancy potential, seizure history, and other medical factors.

Does Lynch syndrome change the answer?

Risk-reducing hysterectomy and ovary removal in a woman with Lynch syndrome who has not had endometrial cancer is a different situation; SGO considers hormone therapy acceptable in that preventive setting. If a woman with Lynch syndrome developed endometrial cancer, the cancer-specific pathology and risk framework on this page still applies.

I was taking HRT when I was diagnosed. Did it cause my cancer?

That cannot be answered from timing alone. Unopposed systemic estrogen in a woman with a uterus increases incident endometrial-cancer risk. Continuous combined estrogen/progestogen produced fewer incident endometrial cancers than placebo in the WHI regimen studied. Many other risk factors and tumor pathways exist. Ask the oncologist to review the exact product, dose, duration, uterus status, and pathology rather than carrying a verdict you cannot prove.

What if I take tamoxifen for breast cancer?

Contact the breast-oncology team. Tamoxifen raises endometrial-cancer risk and also changes which non-hormonal drugs fit. Do not stop it on the basis of this page. The breast-oncology team decides whether the endocrine plan should continue, switch, or stop.

Which symptoms should I report promptly?

New vaginal bleeding or spotting, a new pelvic symptom your surveillance plan tells you to report, symptoms of a blood clot or stroke, or signs of liver injury while taking a monitored non-hormonal drug. Report them to the appropriate clinical team rather than assigning them to menopause yourself.

Still not sure which HRT program is right for you?

Use the free, private Find My HRT Path tool.

It asks about symptoms, uterus status, treatment preference, safety history, insurance, and state. It returns a best-fit online-care route and backup routes with FDA-approved and compounded options clearly separated. Its published safety gates can stop some higher-risk routes, but they do not currently include a dedicated endometrial-cancer question. Treat this diagnosis as specialist-first even if the quiz returns an online option.

Start Find My HRT Path →

No email is required to see the result. The answers are processed in the browser according to the tool's published privacy description. A licensed clinician makes every treatment decision.

It will not tell you HRT is safe after endometrial cancer. What it can do is stop you from choosing the wrong care model before the specialist conversation happens.

Sources

Guidelines and current classification

• Taylor A, Clement K, Hillard T, Sassarini J, et al. British Gynaecological Cancer Society and British Menopause Society guideline: management of menopausal symptoms following treatment of gynaecological cancer. Post Reproductive Health. 2024;30(4):256–279.
• da Silva-Filho AL, Khadilkar S, Divakar H, et al. Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: a FIGO position paper. International Journal of Gynecology & Obstetrics. Published online July 22, 2026. doi:10.1002/ijgo.71188.
• Sinno AK, Pinkerton J, Febbraro T, et al. Hormone therapy in women with gynecologic cancers and women at high risk: Society of Gynecologic Oncology clinical practice statement. Gynecologic Oncology. 2020;157(2):303–306.
• Concin N, Matias-Guiu X, Cibula D, et al. ESGO–ESTRO–ESP guidelines for endometrial carcinoma, 2025 update. The Lancet Oncology. 2025;26(8):e423–e435.

FDA and product information

• U.S. Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products, February 12, 2026.
• U.S. Food and Drug Administration. Divigel prescribing information, revised February 2026.
• U.S. Food and Drug Administration. Divigel prescribing information, revised April 2025.
• U.S. Food and Drug Administration. Estring prescribing information, revised February 2026.
• U.S. Food and Drug Administration. Understanding the risks of compounded drugs.
• U.S. Food and Drug Administration. Veozah prescribing information, revised December 2024.
• U.S. Food and Drug Administration. Lynkuet prescribing information, initial U.S. approval 2025.
• U.S. National Library of Medicine DailyMed. Intrarosa (prasterone) prescribing information.
• U.S. National Library of Medicine DailyMed. Osphena (ospemifene) prescribing information, revised February 2025.

Endometrial-cancer and vaginal-estrogen evidence

• Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen versus placebo after stage I or II endometrial cancer. Journal of Clinical Oncology. 2006;24(4):587–592.
• Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database of Systematic Reviews. 2018;5:CD008830.
• Londero AP, Parisi N, Tassi A, Bertozzi S, Cagnacci A. Hormone replacement therapy in endometrial cancer survivors: a meta-analysis. Journal of Clinical Medicine. 2021;10(14):3165.
• Hsu CD, Yu X, Richardson G, et al. Vaginal estrogen therapy utilization and associated outcomes in younger survivors of endometrial cancer. Menopause. 2026;33(8):865–871.
• Chlebowski RT, Anderson GL, Sarto GE, et al. Continuous combined estrogen plus progestin and endometrial cancer: the Women's Health Initiative randomized trial. Journal of the National Cancer Institute. 2016;108(3):djv350.

Commercial facts and site tools

• Midi Health. Cancer-survivorship care, pricing, insurance, public-program rules, and lab information. Verified August 6, 2026.
• Midi Health. Appointment cancellation and rescheduling policy. Verified August 6, 2026.
• National Cancer Institute SEER. Uterine cancer statistics and median age at diagnosis.
• Winona. HRT options and FDA-approved-versus-compounded status. Verified August 6, 2026.
• Inner Balance. Oestra product and formulation page. Verified August 6, 2026.
• Macmillan Cancer Support Online Community. HRT after endometrial cancer surgery. Used for lived-experience language only, not medical evidence.
• The HRT Index. How Find My HRT Path works.